News

Filter results
E.g., 06/12/2024
E.g., 06/12/2024
07/11/2024
ROVI ACHIEVED OPERATING REVENUE OF 564.6 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 4.7 PERCENTAGE POINTS
31/07/2024
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS
11/07/2024
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s production capacity to 500 million injectables
20/06/2024
ROVI reinforces its heparin production capacity
08/05/2024
ROVI closes the quarter with operating revenue of 151.2 million euros
25/04/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
02/04/2024
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults

Pages